Stock MEDCL MEDINCELL S.A.
Add to a list
To use this feature you must be a member
Log inSign up

All News MedinCell S.A.

Equities

MEDCL

FR0004065605

Market Closed - Euronext Paris
Other stock markets
 11:35:06 2024-05-03 EDT 		After market 13:51:54
14.3 EUR -0.42% Intraday chart for MedinCell S.A. 14.44 +0.98%
04-17 Medincell: share price rises following agreement with AbbVie CF
04-16 Medincell, AbbVie to Co-Develop Injectable Therapeutics DJ

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Medincell: share price rises following agreement with AbbVie
CF
Medincell, AbbVie to Co-Develop Injectable Therapeutics
DJ
Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies
BU
Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies
BU
Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies
CI
Medincell: Unitaid grant to combat malaria
CF
Medincell Receives $6 Million Extension Grant from Unitaid for Malaria Drug Trial
MT
Unitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria
BU
Unitaid Awards Medincell up to $6 million Extension Grant to Fight Malaria
BU
MedinCell to Present at the 23rd Annual Needham Virtual Healthcare Conference
BU
MedinCell to Present at the UBS Virtual CNS Day
BU
Medincell S.A. Reaches Commercial Stage with the Market Launch by Teva of Uzedy? for the Treatment of Schizophrenia
CI
MedinCell: new Chairman of the Supervisory Board
CF
Pharmaceutical Industry Veteran Strategist Philippe Guy Becomes Chairman of MedinCell's Supervisory Board
BU
Medincell S.A. Appoints Philippe Guy as Chairman of Supervisory Board
CI
MedinCell: departure of Chairman of the Supervisory Board
CF
Biopharmaceutical Company MedinCell Chairman Exits
MT
MedinCell Announces Chairman Changes
CI
MedinCell's partner Teva Announces Recruitment Completion of Phase 3 Clinical Study of mdc-TJK Olanzapine Long-Acting Injectable
AQ
Teva Pharmaceutical Industries Ltd. Announces Recruitment Completion of Phase 3 Clinical Study of mdc-TJK / Olanzapine Long-Acting Injectable
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MEDCL Stock
  4. News MedinCell S.A.